Effect of lamivudine in HBeAg-positive chronic hepatitis B: Discordant effect on HBeAg and HBV DNA according to pretreatment ALT level

Figure 1 Cumulative incidence of ALT normalization of groups 1 to 4 by Kaplan-Meier method. Group 1 is indicated by thick line, group 2 by dotted line, group 3 by dashed line, and group 4 by thin line. Groups 1 vs 2, P = NS; groups 1 vs 3, P = 0.002; groups 1 vs 4, P<0.0001; groups 2 vs 3, P = NS; groups 2 vs 4, P = 0.0002; groups 3 vs 4, P = 0.031 (log-rank test).

Figure 2 Cumulative incidence of HBV DNA disappearance of groups 1 to 4 by Kaplan-Meier method. Group 1 is indicated by thick line, group 2 by dotted line, group 3 by dashed line, and group 4 by thin line. Groups 1 vs 2, P = NS (log-rank test).

Figure 3 Cumulative incidence of HBeAg loss of groups 1 to 4 by Kaplan-Meier method. Group 1 is indicated by thick line, group 2 by dotted line, group 3 by dashed line, and group 4 by thin line. Groups 1 vs 2, P = 0.020; groups 1 vs 3, P = NS; groups 2 vs 3, P = NS (log-rank test).

Figure 4 Cumulative incidence of HBeAg seroconversion of groups 1 to 4 by Kaplan-Meier method. Group 1 is indicated by thick line, group 2 by dotted line, group 3 by dashed line, and group 4 by thin line. Groups 1 vs 2, P = 0.048; groups 1 vs 3, P = NS; groups 2 vs 3, P = NS (log-rank test).